公开(公告)号：US20050037463A1

公开(公告)日：2005-02-17

申请号：US10897359

申请日：2004-07-21

Applicant: Avi Ashkenazi ,  Kevin Baker ,  David Botstein ,  Luc Desnoyers ,  Dan Eaton ,  Napoleone Ferrara ,  Ellen Filvaroff ,  Sherman Fong ,  Wei-Qiang Gao ,  Hanspeter Gerber ,  Mary Gerritsen ,  Audrey Goddard ,  Paul Godowski ,  J. Grimaldi ,  Austin Gurney ,  Kenneth Hillan ,  Ivar Kljavin ,  Sophia Kuo ,  Mary Napier ,  James Pan ,  Nicholas Paoni ,  Margaret Roy ,  David Shelton ,  Timothy Stewart ,  Daniel Tumas ,  P. Williams ,  William Wood

Inventor： Avi Ashkenazi ,  Kevin Baker ,  David Botstein ,  Luc Desnoyers ,  Dan Eaton ,  Napoleone Ferrara ,  Ellen Filvaroff ,  Sherman Fong ,  Wei-Qiang Gao ,  Hanspeter Gerber ,  Mary Gerritsen ,  Audrey Goddard ,  Paul Godowski ,  J. Grimaldi ,  Austin Gurney ,  Kenneth Hillan ,  Ivar Kljavin ,  Sophia Kuo ,  Mary Napier ,  James Pan ,  Nicholas Paoni ,  Margaret Roy ,  David Shelton ,  Timothy Stewart ,  Daniel Tumas ,  P. Williams ,  William Wood

IPC: A61K38/00 ,  C07K14/47 ,  C07K14/705 ,  C07H21/04 ,  C12N9/00

CPC classification number: C07K14/4703 ,  A61K38/00 ,  C07K14/47 ,  C07K14/705 ,  C07K2319/00 ,  C07K2319/30 ,  C12N2799/026 ,  C12N2799/027

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

公开(公告)号：US20050014226A1

公开(公告)日：2005-01-20

申请号：US10918851

申请日：2004-08-13

Applicant: Avi Ashkenazi ,  Kevin Baker ,  David Botstein ,  Luc Desnoyers ,  Dan Eaton ,  Napoleone Ferrara ,  Ellen Filvaroff ,  Sherman Fong ,  Wei-Oiang Gao ,  Hanspeter Gerber ,  Mary Gerritsen ,  Audrey Goddard ,  Paul Godowski ,  J. Grimaldi ,  Austin Gurney ,  Kenneth Hillan ,  Ivar Kljavin ,  Sophia Kuo ,  Mary Napier ,  James Pan ,  Nicholas Paoni ,  Margaret Roy ,  David Shelton ,  Timothy Stewart ,  Daniel Tumas ,  P. Williams ,  William Wood

Inventor： Avi Ashkenazi ,  Kevin Baker ,  David Botstein ,  Luc Desnoyers ,  Dan Eaton ,  Napoleone Ferrara ,  Ellen Filvaroff ,  Sherman Fong ,  Wei-Oiang Gao ,  Hanspeter Gerber ,  Mary Gerritsen ,  Audrey Goddard ,  Paul Godowski ,  J. Grimaldi ,  Austin Gurney ,  Kenneth Hillan ,  Ivar Kljavin ,  Sophia Kuo ,  Mary Napier ,  James Pan ,  Nicholas Paoni ,  Margaret Roy ,  David Shelton ,  Timothy Stewart ,  Daniel Tumas ,  P. Williams ,  William Wood

IPC: C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C07H21/04 ,  C12N9/00

CPC classification number: C07K16/18 ,  C07K14/47 ,  C07K14/4703 ,  C07K14/705 ,  C07K2319/00 ,  C07K2319/30 ,  C12N2799/026

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

公开(公告)号：US20050014225A1

公开(公告)日：2005-01-20

申请号：US10858981

申请日：2004-06-01

Applicant: David Botstein ,  Audrey Goddard ,  Paul Godowski ,  J. Grimaldi ,  Austin Gurney ,  Margaret Roy ,  William Wood

Inventor： David Botstein ,  Audrey Goddard ,  Paul Godowski ,  J. Grimaldi ,  Austin Gurney ,  Margaret Roy ,  William Wood

IPC: C07H21/04 ,  C07K14/47 ,  C12N5/06 ,  C12N9/00

CPC classification number: C07K14/47 ,  A61K38/1709

Abstract: The present invention is directed to secreted and transmembrane polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract translation: 本发明涉及分泌和跨膜多肽以及编码这些多肽的核酸分子。 本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明的多肽的嵌合多肽分子，与本发明的多肽结合的抗体以及本发明的多肽的制备方法 发明。

公开(公告)号：US5770426A

公开(公告)日：1998-06-23

申请号：US660986

申请日：1996-06-12

Applicant: Stephen Anderson ,  William F. Bennett ,  David Botstein ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

Inventor： Stephen Anderson ,  William F. Bennett ,  David Botstein ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

IPC: A61K38/00 ,  A61K38/48 ,  C07H21/04 ,  C12N1/21 ,  C12N5/10 ,  C12N9/64 ,  C12N9/72 ,  C12N15/55 ,  C12N15/58 ,  C12N15/63 ,  C12N15/70 ,  C12N15/86

CPC classification number: C12N9/6456 ,  A61K38/00

Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

公开(公告)号：US5714145A

公开(公告)日：1998-02-03

申请号：US733353

申请日：1996-10-17

Applicant: Stephen Anderson ,  William F. Bennett ,  David Botstein ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

Inventor： Stephen Anderson ,  William F. Bennett ,  David Botstein ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

IPC: A61K38/49 ,  C12N9/64 ,  C12N15/58 ,  C12N15/70

CPC classification number: A61K38/49 ,  C12N15/70 ,  C12N9/64

Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

公开(公告)号：US5616486A

公开(公告)日：1997-04-01

申请号：US422736

申请日：1995-04-14

Applicant: Stephen Anderson ,  William F. Bennett ,  David Botstein ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

Inventor： Stephen Anderson ,  William F. Bennett ,  David Botstein ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

IPC: A61K38/00 ,  A61K38/48 ,  C07H21/04 ,  C12N1/21 ,  C12N5/10 ,  C12N9/64 ,  C12N9/72 ,  C12N15/55 ,  C12N15/58 ,  C12N15/63 ,  C12N15/70 ,  C12N15/86

CPC classification number: C12N9/6456 ,  A61K38/00

Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

公开(公告)号：US5262170A

公开(公告)日：1993-11-16

申请号：US770510

申请日：1991-10-03

Applicant: Stephen Anderson ,  William F. Bennett ,  David Botstein ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

Inventor： Stephen Anderson ,  William F. Bennett ,  David Botstein ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

IPC: A61K38/00 ,  A61K38/48 ,  C07H21/04 ,  C12N1/21 ,  C12N5/10 ,  C12N9/64 ,  C12N9/72 ,  C12N15/55 ,  C12N15/58 ,  C12N15/63 ,  C12N15/70 ,  C12N15/86 ,  A61K37/547

CPC classification number: C12N9/6456 ,  A61K38/00

Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

Abstract translation: 制备组织纤溶酶原激活剂（t-PA）酶原和变体，包括t-PA的纤维蛋白溶解活性变体，其在t-PA的蛋白酶结构域内的位置具有氨基酸改变，与相应的野生型t- PA，与相应的野生型t-PA相比，其改变使纤维蛋白溶酶原纤维蛋白原和/或纤维蛋白（或血浆凝块）存在下的变形酶原。 可以制备编码酶原和变体的DNA序列，以及掺入DNA序列的表达载体和用表达载体转化的宿主细胞。 酶原和变体可用于药物制剂中以治疗血管疾病或病症或预防纤维蛋白沉积或哺乳动物中的粘附形成或重新形成。